A Role for IRF4 in the Development of CLL

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Aug 9

PMID 23926303

Citations 24

Authors

Vipul Shukla

Shibin Ma

Richard R Hardy

Shantaram S Joshi

Runqing Lu

Affiliations

Soon will be listed here.

Abstract

Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator of B-cell development and function. A recent genome-wide single-nucleotide polymorphism (SNP) association study identified IRF4 as a major susceptibility gene in chronic lymphocytic leukemia (CLL). Although the SNPs located in the IRF4 gene were linked to a downregulation of IRF4 in CLL patients, whether a low level of IRF4 is critical for CLL development remains unclear. In rodents, CLL cells are derived from B1 cells whose population is dramatically expanded in immunoglobulin heavy chain Vh11 knock-in mice. We bred a Vh11 knock-in allele into IRF4-deficient mice (IRF4(-/-)Vh11). Here, we report that IRF4(-/-)Vh11 mice develop spontaneous early-onset CLL with 100% penetrance. Further analysis shows that IRF4(-/-)Vh11 CLL cells proliferate predominantly in spleen and express high levels of Mcl-1. IRF4(-/-)Vh11 CLL cells are resistant to apoptosis but reconstitution of IRF4 expression in the IRF4(-/-)Vh11 CLL cells inhibits their survival. Thus, our study demonstrates for the first time a causal relationship between low levels of IRF4 and the development of CLL. Moreover, our findings establish IRF4(-/-)Vh11 mice as a novel mouse model of CLL that not only is valuable for dissecting molecular pathogenesis of CLL but could also be used for therapeutic purposes.

Citing Articles

Research and analysis of differential gene expression in CD34 hematopoietic stem cells in myelodysplastic syndromes.

Wang M, Liao C, Wei X, Xie Y, Han P, Yu Y PLoS One. 2025; 20(3):e0315408.

PMID: 40073065 PMC: 11902259. DOI: 10.1371/journal.pone.0315408.

The dynamic functions of IRF4 in B cell malignancies.

Maffei R, Fiorcari S, Atene C, Martinelli S, Mesini N, Pilato F Clin Exp Med. 2022; 23(4):1171-1180.

PMID: 36495369 PMC: 10390622. DOI: 10.1007/s10238-022-00968-0.

Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.

Bristol J, Brand J, Ohashi M, Eichelberg M, Casco A, Nelson S PLoS Pathog. 2022; 18(4):e1010453.

PMID: 35472072 PMC: 9041801. DOI: 10.1371/journal.ppat.1010453.

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1.

Fiorcari S, Maffei R, Atene C, Mesini N, Maccaferri M, Leonardi G Front Oncol. 2022; 11:777587.

PMID: 35070982 PMC: 8770925. DOI: 10.3389/fonc.2021.777587.

Molecular interactions of IRF4 in B cell development and malignancies.

Sundararaj S, Casarotto M Biophys Rev. 2022; 13(6):1219-1227.

PMID: 35059038 PMC: 8724474. DOI: 10.1007/s12551-021-00825-6.

References

Hardy R, Wei C, Hayakawa K . Selection during development of VH11+ B cells: a model for natural autoantibody-producing CD5+ B cells. Immunol Rev. 2004; 197:60-74. DOI: 10.1111/j.0105-2896.2004.0100.x. View

Laine J, Kunstle G, Obata T, Sha M, Noguchi M . The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000; 6(2):395-407. DOI: 10.1016/s1097-2765(00)00039-3. View

Chen S, Batliwalla F, Holodick N, Yan X, Yancopoulos S, Croce C . Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. Proc Natl Acad Sci U S A. 2013; 110(16):E1500-7. PMC: 3631671. DOI: 10.1073/pnas.1300616110. View

Allan J, Sunter N, Bailey J, Pettitt A, Harris R, Pepper C . Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukemia. 2010; 24(4):877-81. DOI: 10.1038/leu.2009.298. View

Longo P, Laurenti L, Gobessi S, Sica S, Leone G, Efremov D . The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2007; 111(2):846-55. DOI: 10.1182/blood-2007-05-089037. View

Martin-Subero J, Lopez-Otin C, Campo E . Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr Opin Hematol. 2013; 20(4):362-8. DOI: 10.1097/MOH.0b013e32836235dc. View

Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T . The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010; 17(1):28-40. DOI: 10.1016/j.ccr.2009.11.019. View

Ma S, Pathak S, Mandal M, Trinh L, Clark M, Lu R . Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 2010; 30(17):4149-58. PMC: 2937562. DOI: 10.1128/MCB.00224-10. View

Chang C, Lorek J, Sabath D, Li Y, Chitambar C, Logan B . Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood. 2002; 100(13):4671-5. DOI: 10.1182/blood-2002-01-0104. View

10.

Kipps T . Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol. 2003; 10(4):312-8. DOI: 10.1097/00062752-200307000-00010. View

11.

Ghia P, Chiorazzi N, Stamatopoulos K . Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008; 264(6):549-62. DOI: 10.1111/j.1365-2796.2008.02030.x. View

12.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

13.

Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L . IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011; 118(10):2827-9. PMC: 3172799. DOI: 10.1182/blood-2011-04-350579. View

14.

Herling M, Patel K, Khalili J, Schlette E, Kobayashi R, Medeiros L . TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2005; 20(2):280-5. DOI: 10.1038/sj.leu.2404017. View

15.

Bichi R, Shinton S, Martin E, Koval A, Calin G, Cesari R . Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002; 99(10):6955-60. PMC: 124510. DOI: 10.1073/pnas.102181599. View

16.

Crowther-Swanepoel D, Broderick P, Ma Y, Robertson L, Pittman A, Price A . Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet. 2010; 19(9):1840-5. DOI: 10.1093/hmg/ddq044. View

17.

Bhat N, Bieber M, Spellerberg M, Stevenson F, Teng N . Recognition of auto- and exoantigens by V4-34 gene encoded antibodies. Scand J Immunol. 2000; 51(2):134-40. DOI: 10.1046/j.1365-3083.2000.00654.x. View

18.

Chiorazzi N, Hatzi K, Albesiano E . B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci. 2006; 1062:1-12. DOI: 10.1196/annals.1358.002. View

19.

Guchhait P, Lopez J, Thiagarajan P . Characterization of autoantibodies against sulfatide from a V-gene phage-display library derived from patients with systemic lupus erythematosus. J Immunol Methods. 2005; 295(1-2):129-37. DOI: 10.1016/j.jim.2004.10.001. View

20.

Wen L, Shinton S, Hardy R, Hayakawa K . Association of B-1 B cells with follicular dendritic cells in spleen. J Immunol. 2005; 174(11):6918-26. DOI: 10.4049/jimmunol.174.11.6918. View